- Drug bioavailability enhancement technology developer Lexaria Bioscience is working to increase the number of potential new solutions to unmet medical needs and improving existing treatments for other chronic conditions
- Lexaria’s patented DehydraTECH solution transforms a wide variety of orally and topically administered products into enhanced solutions that make the active pharmaceutical ingredients (“APIs”) more rapidly available and effective at lower doses
- DehydraTECH-enhanced products have also demonstrated the ability to cross the blood-brain barrier through fatty acid transport proteins
- The company’s ongoing series of tests of different DehydraTECH-enhanced products has led to a pre-IND filing with the FDA for a prospective registered treatment for hypertension, while other anticipated potential therapies target seizures, nicotine addiction and erectile dysfunction
The COVID pandemic that roiled the world’s healthcare systems during the past two years (and appears to be hospitalizing an increasing number of patients again (https://ibn.fm/6cYVm) revealed a marked demand for repurposing existing drugs for unanticipated treatments, particularly prior to the provisional development of various targeted vaccines to combat the novel coronavirus (https://ibn.fm/A4nIU).
New data analysis has revealed the potential for several existing biopharma products to be repositioned to treat patients with unmet medical needs, potentially opening the way for dozens of new solutions to chronic medical conditions (https://ibn.fm/4gSz3).
At the same time, drug technology innovator Lexaria Bioscience (NASDAQ: LEXX) is finding ways to make available pharmaceuticals and wellness products more effective at doing what they do to treat patient needs, helping to expand the range of potential solutions to chronic health concerns and unmet medical needs.
Lexaria’s patented DehydraTECH product is a technology used to increase the bioavailability of drugs administered orally or transdermally while adding zero chemical byproducts.
The company’s ongoing testing is delivering data that demonstrates the DehydraTECH-enhanced products’ ability to take effect faster and more potently in placebo-controlled and double-blinded human clinical trials.
As an example of some of Lexaria’s testing, a series of studies have advanced its investigation of DehydraTECH-CBD from lab animal to human subject stage as a potential treatment for hypertension (heart disease-related high blood pressure) and the company is pursuing a pre-Investigational New Drug (“IND”) meeting with the U.S. Food and Drug Administration (“FDA”) to file its product as a prospective registered treatment this year (https://ibn.fm/QGuqS).
Another series of tests involve the DehydraTECH-nicotine oral pouch. Smoked nicotine is the world’s leading avoidable cause of death, but non-combusted oral nicotine is dramatically less harmful. is being advanced as a non-inhaled but rapidly available Lexaria’s DehydraTECH-nicotine oral pouch is being tested this summer in a human clinical study against existing leading product brands including Zyn (Swedish Match) and ON! (Altria). Lexaria expects its DehyraTECH processed and purified nicotine to work faster than leading brands, delivering higher levels of consumer satisfaction.
Another R&D program is pitting DehydraTECH-CBD against generic CBD and Epidiolex to evaluate DehydraTECH’s ability to improve treatments for epileptic seizures – that testing will be ongoing throughout much of 2022. And if all that isn’t enough, antiviral research shows DehydraTECH enhanced versions of Remdesivir and Ebastine were effective at inhibiting COVID’s SARS- CoV-2 virus and improving their delivery into bloodstream, as well as that of Darunavir and Efavirenz, which are used in treating HIV / AIDS and regarded as potential COVID therapies (https://ibn.fm/tEGBs).
With the expanding reach of the company’s research, Lexaria is optimistic its patented technology for delivering APIs into the bloodstream and across the blood-brain barrier with reduced liver metabolization — adaptable to multiple ingestible product formats such as tablets, capsules, oral suspensions and mouth-melts — will prove disruptive to the pharmaceutical industry.
All planned Lexaria operations are fully funded through Q3 2023 at this time.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.
To receive SMS text alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.TinyGems.com
TinyGems is part of the InvestorBrandNetwork